Management of Peripheral Vascular Disease

All patients with peripheral arterial disease must receive comprehensive cardiovascular risk reduction—including antiplatelet therapy, high-intensity statin, blood pressure control, smoking cessation, and supervised exercise training—as first-line treatment for at least 3 months before any revascularization is considered. 1, 2

Initial Assessment

Perform a systematic vascular evaluation that includes:

Symptom review: walking distance to claudication onset, presence of rest pain, non-healing wounds, and functional limitations in work or daily activities 1, 2
Comprehensive pulse examination: palpate all lower extremity pulses (femoral, popliteal, dorsalis pedis, posterior tibial) 1
Direct foot inspection: remove shoes and socks to examine for ulcers, skin breakdown, or signs of ischemia 1
Ankle-brachial index (ABI): ABI ≤0.90 confirms PAD; if ABI is normal but suspicion remains high, obtain post-exercise ABI (>20% decrease is diagnostic) 1
Toe-brachial index: use when vessels are non-compressible (ABI >1.40, common in diabetes) 1
Blood pressure in both arms: difference >15-20 mmHg suggests subclavian stenosis 1

Antiplatelet Therapy (Mandatory for All PAD Patients)

Clopidogrel 75 mg once daily is the preferred antiplatelet agent to reduce myocardial infarction, stroke, and vascular death in all symptomatic PAD patients. 3, 1, 2, 4

Aspirin 75-325 mg daily is an acceptable alternative only when clopidogrel is contraindicated or not tolerated. 3, 1, 4
In high-risk PAD patients without high bleeding risk, particularly after lower-limb revascularization, add rivaroxaban 2.5 mg twice daily to aspirin 100 mg daily to further reduce cardiovascular and limb events. 1, 2
Do NOT use routine dual antiplatelet therapy (aspirin + clopidogrel) in stable PAD—it increases major bleeding without cardiovascular benefit. 2, 4
Do NOT add warfarin to antiplatelet therapy—it provides no benefit and markedly increases major bleeding risk. 2, 4

Lipid Management (Mandatory for All PAD Patients)

Initiate high-intensity statin therapy immediately upon PAD diagnosis, regardless of baseline cholesterol levels. 1, 4

Target LDL-C <70 mg/dL (<1.8 mmol/L) in very high-risk patients. 2
If target is not met on maximally tolerated statin, add ezetimibe. 2
If LDL-C remains elevated after statin + ezetimibe, add a PCSK9 inhibitor (evolocumab or alirocumab). 2
For statin-intolerant patients, use bempedoic acid alone or combined with a PCSK9 inhibitor. 2
Fibrates are NOT recommended for cholesterol lowering in PAD. 2

Statins also improve claudication symptoms by increasing walking distance. 3

Blood Pressure Control

Target blood pressure <140/90 mmHg in patients without diabetes, or <130/80 mmHg in patients with diabetes or chronic kidney disease. 3, 1, 4

ACE inhibitors or ARBs are first-line agents because they reduce cardiovascular events and may improve walking distance. 3, 2, 4
Beta-blockers are NOT contraindicated in PAD—they are safe, effective antihypertensive agents and do not worsen claudication. 3, 1, 4
In patients ≥85 years, with severe frailty, or symptomatic orthostatic hypotension, a more lenient target (<140/90 mmHg) may be appropriate. 2

Smoking Cessation (Critical Priority)

Screen for tobacco use at every clinical encounter. 1, 4

Provide counseling and develop a comprehensive quit plan. 3, 4
Offer pharmacotherapy: varenicline, bupropion, or nicotine replacement therapy unless contraindicated. 3, 1, 4
Ongoing smoking raises five-year mortality to 40-50% in symptomatic PAD. 4

Diabetes Management

Target HbA1c <7% to reduce microvascular complications (nephropathy, retinopathy) and potentially improve cardiovascular outcomes. 3, 1, 4

SGLT2 inhibitors and GLP-1 receptor agonists with proven cardiovascular benefit should be used in patients with type 2 diabetes and PAD. 2
Implement daily foot care: appropriate footwear, podiatric care, daily foot inspection, skin cleansing, topical moisturizers, and urgent treatment of any lesions or ulcerations. 3, 1, 4
Patients with diabetes and PAD have a 7- to 15-fold higher risk of amputation compared with non-diabetic individuals. 4

Supervised Exercise Training (First-Line Treatment for Claudication)

Supervised exercise training (SET) is the initial treatment for intermittent claudication and must be attempted before any revascularization. 1, 2, 4

Prescription Parameters (All Class I, Level A):

Frequency: ≥3 sessions per week 1, 2
Duration: 30-60 minutes per session 1, 2, 4
Program length: minimum 12 weeks 1, 2, 4
Intensity: high-intensity (77-95% of maximal heart rate or Borg 14-17) yields the greatest improvements in walking performance and cardiorespiratory fitness 1, 2
Modality: walking is the first-line training activity 1, 2
Pain level: exercise to moderate-severe claudication pain to maximize walking distance gains 1, 2

When SET is unavailable, structured home-based exercise training (HBET) with remote monitoring (telephone, logbooks, or connected devices) may be offered, although it is inferior to supervised programs. 1, 2

Evidence: The CLEVER trial demonstrated that supervised exercise produced superior treadmill walking performance at 6 months compared with primary stenting for aorto-iliac PAD. 2 A Dutch retrospective cohort of 54,504 patients showed that revascularization was associated with higher rates of secondary procedures and increased 5-year mortality versus SET alone. 2

Pharmacologic Therapy for Claudication Symptoms

Cilostazol 100 mg twice daily should be prescribed for all patients with lifestyle-limiting claudication to improve symptoms and walking distance. 3, 1, 2, 4

Cilostazol is absolutely contraindicated in patients with any degree of heart failure because of its phosphodiesterase-III inhibition. 2, 4
Pentoxifylline 400 mg three times daily may be used as a second-line alternative only when cilostazol is contraindicated, although its clinical benefit is marginal and not well established. 3, 2
Other agents (L-arginine, propionyl-L-carnitine, ginkgo biloba) have marginal or unestablished effectiveness, and chelation therapy is not indicated and may be harmful. 2

Indications for Revascularization (Only After 3-Month Trial of Optimal Medical Therapy)

Revascularization should be considered ONLY after a 3-month trial of optimal medical therapy and supervised exercise in patients with persistent lifestyle-limiting symptoms and impaired quality of life. 1, 2, 4

Mandatory Criteria Before Proceeding (All Must Be Met):

Completion of supervised exercise and pharmacotherapy with inadequate symptomatic response 3, 1, 2
Significant disability affecting work or important daily activities 3, 1, 2
Ongoing comprehensive risk-factor modification and antiplatelet therapy 3, 1, 2
Lesion anatomy presenting low procedural risk and high probability of immediate and long-term technical success 3, 1, 2

After the 3-month period, reassess PAD-related quality of life; revascularization may be pursued if quality of life remains impaired. 2

Revascularization Strategy:

For femoro-popliteal lesions, drug-eluting endovascular therapy is the preferred first-line strategy. 2
Open surgical bypass using autologous vein should be considered in low-risk patients when a suitable vein is available. 2
For TASC type A iliac and femoropopliteal lesions, endovascular intervention is preferred. 1

Revascularization is NOT recommended solely to prevent progression to critical limb-threatening ischemia (CLTI) and is NOT indicated in asymptomatic PAD. 2

Critical Limb-Threatening Ischemia (CLTI) – Medical Emergency

Early recognition of CLTI and immediate referral to a vascular team are essential for limb salvage. 3, 1, 2

Management:

Expedited evaluation of amputation-risk factors (diabetes, neuropathy, chronic renal failure, infection) 3, 2
Prompt revascularization should be performed as soon as possible to restore direct pulsatile flow to at least one foot artery, preferably the artery supplying the wound region 2
Systemic antibiotics should be started promptly in CLTI patients with skin ulcerations or evidence of infection 3, 1, 2
Off-loading of mechanical tissue stress is indicated for CLTI-related ulcers to facilitate wound healing 2
Referral to specialized wound-care providers 3
Patients at risk for CLTI (ABI <0.4 with diabetes or any diabetic with known PAD) should undergo regular foot inspection 3, 1, 2
Patients with a prior history of CLI or who have undergone successful CLI treatment should be evaluated at least twice yearly by a vascular specialist due to high recurrence risk 3, 1, 2, 4
Patients at risk for CLTI (diabetes, neuropathy, chronic renal failure, infection) who develop acute limb symptoms represent potential vascular emergencies and should be assessed immediately 3

"Time is tissue"—infected ischemic diabetic foot ulcers should be treated as a medical urgency, preferably within 24 hours. 2

Acute Limb Ischemia – Vascular Emergency

In patients with acute limb ischemia and a salvageable extremity, emergent evaluation of the occlusion level and prompt endovascular or surgical revascularization are required. 2

Early anticoagulation is recommended to limit thrombus propagation until definitive therapy can be performed. 2
Cross-sectional imaging (CTA or MRA) is recommended to define the exact nature and level of thrombosis and underlying atherosclerotic plaque. 2
If the limb is non-viable, revascularization attempts should not be performed. 2

Follow-Up and Surveillance

All PAD patients should have at least annual follow-up to assess clinical status, medication adherence, limb symptoms, and cardiovascular risk factors; duplex ultrasound is performed as needed. 1, 2, 4
Post-CLI patients should be evaluated at least twice annually by a vascular specialist due to high recurrence risk. 3, 1, 2, 4
Long-term patency of infra-inguinal bypass grafts should be monitored through a surveillance program that includes vascular history, resting ABI, physical examination, and periodic duplex ultrasound. 1, 2
Patients at risk for or treated for CLTI should receive verbal and written instructions for self-surveillance of recurrence. 3, 2

Common Pitfalls to Avoid

Do NOT proceed directly to revascularization without first completing a 3-month trial of optimal medical therapy and supervised exercise in patients with intermittent claudication. 2
Do NOT add warfarin to antiplatelet therapy without a clear indication—it increases bleeding risk without cardiovascular benefit. 2, 4
Do NOT prescribe cilostazol to patients with heart failure—it is absolutely contraindicated. 2, 4
Do NOT delay referral to a vascular team in patients with CLTI—early recognition and treatment are critical for limb salvage. 2
Do NOT withhold beta-blockers—they are safe and effective in PAD. 3, 1, 4
Do NOT use routine dual antiplatelet therapy—it raises bleeding risk without clear benefit. 2, 4

How should peripheral vascular disease be managed?

Help us tailor your experience